Developer docs
API playgroundTry for free, no card

Search company profiles

Etcembly

Full company profile

uuid0008wzh

Namestring
Etcembly
Legal namestring
Etcembly Limited
Websiteurl
etcembly.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Etcembly Limited is a UK-based techbio company founded in 2020 and headquartered at the Harwell Campus in Oxfordshire, building AI tooling for biologics discovery. Its core product, EMLy Co-pilot, is a conversational AI platform that unifies antibody and T-cell receptor (TCR) design workflows — replacing dozens of discrete bioinformatics and computational tools with a single natural-language interface. The platform combines proprietary structural modeling, variant generation, biologics optimization (for stability, expression, and manufacturability), and ML models trained on immune datasets, and is positioned to serve both nimble seed-stage biotechs and global pharma R&D organizations.

The company's commercial model combines self-serve SaaS subscription (tiered pricing on the EMLy platform) with a consultative enterprise sales motion offering guided walkthrough demos and Custom Workflows engagements (proprietary immune sequencing, functional immune discovery, antibody expression enhancement, co-complex prediction). The founding team's credentials — credited with contributions to 20+ FDA-approved therapies — anchor the credibility of the platform in real-world drug development. The most material commercial and scientific proof point is the collaboration with Oslo-listed Zelluna, whose AI-optimized TCR-NK candidate ZI-MA4-1 received UK MHRA approval for clinical testing in February 2026, followed by an expanded partnership targeting the KKLC1 cancer antigen in March 2026.

Etcembly's strategic posture is that of an early-stage, pre-funding-disclosure AI-native discovery platform. It operates from the Oxford Science Park AI cohort (joined July 2024), runs a Long-Term Survivor Study (launched September 2024) to generate proprietary immune sequencing data, and has built a partnership ecosystem including Vector Laboratories (technology integration) and Finnoah PR (communications). With 11-50 employees, no disclosed funding rounds, and only two named customers, the company remains in an early commercial phase while pursuing regulatory-grade validation through partner-led clinical programs.

Short descriptiontext

Etcembly is a UK-based AI-native techbio company whose EMLy Co-pilot platform unifies antibody and T-cell receptor design workflows into a single conversational interface, serving biotech and pharma R&D organizations with proprietary structural modeling, variant generation, and biologics optimization capabilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHanwell, United Kingdom
HQ citystring
Hanwell
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI biologics discovery, antibody engineering platform, TCR therapeutics design, computational immunology, biotech AI software
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Computer Systems Design Services541512
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI Biologics Discovery Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1EMLy Co-pilot Platform Access
TypeSubscription Recurring
Description

SaaS-based AI platform for biologics discovery offered via subscription with tiered pricing. The company offers guided walkthrough demos and custom workflow engagements, suggesting both self-serve and enterprise licensing models.

etcembly.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Etcembly provides EMLy Co-pilot, an AI-powered SaaS platform that unifies biologics design workflows—including antibody, T-cell receptor (TCR), and other protein engineering—into a single conversational interface. The platform performs proprietary structural modeling, variant generation, and biologics optimisation to help scientists design development-ready therapeutic candidates. Complementing the platform, Etcembly offers Custom Workflows for bespoke AI-driven discovery services such as proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Discovery timeline compressed from weeks to minutes
+1 more record
Product overview1 text field

Etcembly offers EMLy Co-pilot as its core AI platform, which unifies biologics design workflows into a single conversational interface. The platform is complemented by Custom Workflows services that provide bespoke solutions including proprietary immune sequencing, functional immune discovery, and antibody expression enhancement. The product portfolio supports multiple modalities (mAbs, TCRs) across the drug discovery pipeline from target hypothesis through clinical lead optimization and CMC.

Product and service2 records
1EMLy Co-pilot
CategoryAI Biologics Discovery Software
Description

An integrated AI platform that unifies biologics design workflows into a single conversational experience, enabling scientists to decode, predict, and design development-ready therapeutic candidates across target-to-hit, hit-to-lead, and clinical lead optimization stages. Supports multiple modalities including monoclonal antibodies (mAbs), T-cell receptors (TCRs), and other biologics, and is targeted at biotech and pharmaceutical R&D organizations.

2Custom Workflows
CategoryBespoke Computational Biology Services
Description

Tailored AI-driven biologics discovery services for clients requiring bespoke computational workflows, including proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction. Targeted at biotech and pharma organizations needing project-specific computational biology engagements.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Zelluna, a Norwegian biotech company listed on the Oslo Stock Exchange, collaborated with Etcembly for AI-enabled T-cell receptor engineering. The collaboration builds on their previous successful partnership that produced ZI-MA4-1, which received UK MHRA approval for clinical testing in February 2026. The expanded partnership targets the KKLC1 cancer antigen for use in allogeneic TCR-NK cell therapy platform for treating solid cancers. In-vitro data from the new KKLC1 program expected in Q4 2026.

Strategic tierMinorTypeOthersAnnounced on2025-02-21
Description

Manchester-based communications agency Finnoah PR was appointed by Etcembly for public relations services. Finnoah PR is described as a Manchester comms agency serving the technology and biotech sectors.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI protein design platform helping scientists engineer biologics with improved properties. Comparable as an emerging player offering generative AI tools for protein engineering, partially overlapping Etcembly's biologics optimization capabilities.

TypeDirect peer
Description

UK-based AI-driven antibody discovery company combining ML, robotics, and synthetic biology. Highly comparable to Etcembly as a fellow UK techbio applying ML to antibody engineering with enterprise pharma customers.

TypeDirect peer
Description

AI/ML-driven drug discovery company combining ML with biological data to accelerate therapeutic development. Closely comparable to Etcembly in applying machine learning to biologics and small-molecule discovery workflows.

4Antiverse
TypeEmerging player
Description

UK-based early-stage company using AI/ML to design antibody therapeutics. Comparable as an emerging AI-antibody-design peer based in the same UK ecosystem with overlapping target customers.

TypeOthers
Description

AI-powered scientific research platform for life-science R&D. Comparable as an AI-enabling layer for biotech scientists, though focused on experiment/reagent selection rather than de novo biologics design.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company building on DeepMind's protein-structure models. Comparable as a broad incumbent applying AI to biologics design, with significantly greater resources than Etcembly.

TypeBroad incumbent
Description

Public AI-driven drug discovery company combining high-throughput biology with ML across multiple therapeutic areas. Comparable as a broad incumbent using AI/ML across discovery, though with a stronger small-molecule and phenotypic-screening orientation than Etcembly.

TypeDirect peer
Description

Generative AI platform for designing novel protein therapeutics across multiple modalities. Directly comparable to Etcembly in using ML to design biologics (antibodies, enzymes, peptides) for pharma partners.

TypeDirect peer
Description

AI-driven antibody engineering platform combining wet-lab high-throughput experimentation with ML. Highly comparable to Etcembly's EMLy platform in target customer (biologics developers), technology (ML-guided protein engineering), and modality focus (antibodies).

TypeBroad incumbent
Description

Public clinical-stage antibody discovery platform using data engineering and ML to identify antibody candidates. Comparable as a broader incumbent in ML-enabled antibody discovery serving large pharma partners.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Etcembly

AI Biologics Discovery Softwareetcembly.com

Etcembly is a UK-based AI-native techbio company whose EMLy Co-pilot platform unifies antibody and T-cell receptor design workflows into a single conversational interface, serving biotech and pharma R&D organizations with proprietary structural modeling, variant generation, and biologics optimization capabilities.

What Etcembly does

Etcembly Limited is a UK-based techbio company founded in 2020 and headquartered at the Harwell Campus in Oxfordshire, building AI tooling for biologics discovery. Its core product, EMLy Co-pilot, is a conversational AI platform that unifies antibody and T-cell receptor (TCR) design workflows — replacing dozens of discrete bioinformatics and computational tools with a single natural-language interface. The platform combines proprietary structural modeling, variant generation, biologics optimization (for stability, expression, and manufacturability), and ML models trained on immune datasets, and is positioned to serve both nimble seed-stage biotechs and global pharma R&D organizations.

The company's commercial model combines self-serve SaaS subscription (tiered pricing on the EMLy platform) with a consultative enterprise sales motion offering guided walkthrough demos and Custom Workflows engagements (proprietary immune sequencing, functional immune discovery, antibody expression enhancement, co-complex prediction). The founding team's credentials — credited with contributions to 20+ FDA-approved therapies — anchor the credibility of the platform in real-world drug development. The most material commercial and scientific proof point is the collaboration with Oslo-listed Zelluna, whose AI-optimized TCR-NK candidate ZI-MA4-1 received UK MHRA approval for clinical testing in February 2026, followed by an expanded partnership targeting the KKLC1 cancer antigen in March 2026.

Etcembly's strategic posture is that of an early-stage, pre-funding-disclosure AI-native discovery platform. It operates from the Oxford Science Park AI cohort (joined July 2024), runs a Long-Term Survivor Study (launched September 2024) to generate proprietary immune sequencing data, and has built a partnership ecosystem including Vector Laboratories (technology integration) and Finnoah PR (communications). With 11-50 employees, no disclosed funding rounds, and only two named customers, the company remains in an early commercial phase while pursuing regulatory-grade validation through partner-led clinical programs.

Etcembly firmographics

Firmographics
Name
Etcembly
Legal name
Etcembly Limited
Website
https://etcembly.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Etcembly is a UK-based AI-native techbio company whose EMLy Co-pilot platform unifies antibody and T-cell receptor design workflows into a single conversational interface, serving biotech and pharma R&D organizations with proprietary structural modeling, variant generation, and biologics optimization capabilities.
Ownership category
akta.pro rank

Etcembly industry classification

Industry
Product category
AI Biologics Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Computer Systems Design Services (541512)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI biologics discovery
  • Antibody engineering platform
  • TCR therapeutics design
  • Computational immunology
  • Biotech AI software

Where Etcembly is headquartered

Location

Headquarters

HQ city
Hanwell
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Etcembly business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. EMLy Co-pilot Platform Access: SaaS-based AI platform for biologics discovery offered via subscription with tiered pricing. The company offers guided walkthrough demos and custom workflow engagements, suggesting both self-serve and enterprise licensing models.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Etcembly product offering

Product offering

Core offering

Etcembly provides EMLy Co-pilot, an AI-powered SaaS platform that unifies biologics design workflows—including antibody, T-cell receptor (TCR), and other protein engineering—into a single conversational interface. The platform performs proprietary structural modeling, variant generation, and biologics optimisation to help scientists design development-ready therapeutic candidates. Complementing the platform, Etcembly offers Custom Workflows for bespoke AI-driven discovery services such as proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction.

Product overview

Etcembly offers EMLy Co-pilot as its core AI platform, which unifies biologics design workflows into a single conversational interface. The platform is complemented by Custom Workflows services that provide bespoke solutions including proprietary immune sequencing, functional immune discovery, and antibody expression enhancement. The product portfolio supports multiple modalities (mAbs, TCRs) across the drug discovery pipeline from target hypothesis through clinical lead optimization and CMC.

Differentiator

Problem solved

Functional benefit

Products and services

  • EMLy Co-pilot An integrated AI platform that unifies biologics design workflows into a single conversational experience, enabling scientists to decode, predict, and design development-ready therapeutic candidates across target-to-hit, hit-to-lead, and clinical lead optimization stages. Supports multiple modalities including monoclonal antibodies (mAbs), T-cell receptors (TCRs), and other biologics, and is targeted at biotech and pharmaceutical R&D organizations.
  • Custom Workflows Tailored AI-driven biologics discovery services for clients requiring bespoke computational workflows, including proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction. Targeted at biotech and pharma organizations needing project-specific computational biology engagements.

Quantifiable outcome

  • Discovery timeline compressed from weeks to minutes
  • +1 more outcomes

Companies that use Etcembly

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Etcembly technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Etcembly partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • ZellunacoreStrategic or Co-development Partner · 9 March 2026Zelluna, a Norwegian biotech company listed on the Oslo Stock Exchange, collaborated with Etcembly for AI-enabled T-cell receptor engineering. The collaboration builds on their previous successful partnership that produced ZI-MA4-1, which received UK MHRA approval for clinical testing in February 2026. The expanded partnership targets the KKLC1 cancer antigen for use in allogeneic TCR-NK cell therapy platform for treating solid cancers. In-vitro data from the new KKLC1 program expected in Q4 2026.
  • Finnoah PRminorOthers · 21 February 2025Manchester-based communications agency Finnoah PR was appointed by Etcembly for public relations services. Finnoah PR is described as a Manchester comms agency serving the technology and biotech sectors.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Etcembly competitors and assessment

Company assessment

Emerging players

  • Cradle Bio: AI protein design platform helping scientists engineer biologics with improved properties. Comparable as an emerging player offering generative AI tools for protein engineering, partially overlapping Etcembly's biologics optimization capabilities.
  • Antiverse: UK-based early-stage company using AI/ML to design antibody therapeutics. Comparable as an emerging AI-antibody-design peer based in the same UK ecosystem with overlapping target customers.

Direct peers

  • LabGenius: UK-based AI-driven antibody discovery company combining ML, robotics, and synthetic biology. Highly comparable to Etcembly as a fellow UK techbio applying ML to antibody engineering with enterprise pharma customers.
  • Insitro: AI/ML-driven drug discovery company combining ML with biological data to accelerate therapeutic development. Closely comparable to Etcembly in applying machine learning to biologics and small-molecule discovery workflows.
  • Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple modalities. Directly comparable to Etcembly in using ML to design biologics (antibodies, enzymes, peptides) for pharma partners.
  • BigHat Biosciences: AI-driven antibody engineering platform combining wet-lab high-throughput experimentation with ML. Highly comparable to Etcembly's EMLy platform in target customer (biologics developers), technology (ML-guided protein engineering), and modality focus (antibodies).

Others

  • BenchSci: AI-powered scientific research platform for life-science R&D. Comparable as an AI-enabling layer for biotech scientists, though focused on experiment/reagent selection rather than de novo biologics design.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's protein-structure models. Comparable as a broad incumbent applying AI to biologics design, with significantly greater resources than Etcembly.
  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with ML across multiple therapeutic areas. Comparable as a broad incumbent using AI/ML across discovery, though with a stronger small-molecule and phenotypic-screening orientation than Etcembly.
  • AbCellera Biologics: Public clinical-stage antibody discovery platform using data engineering and ML to identify antibody candidates. Comparable as a broader incumbent in ML-enabled antibody discovery serving large pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Etcembly social profiles

Digital presence

Etcembly financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Etcembly leadership team

Management profile

Number of profiles

Profiles2 records

Etcembly funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Etcembly M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Etcembly

What does Etcembly do?

Etcembly provides EMLy Co-pilot, an AI-powered SaaS platform that unifies biologics design workflows—including antibody, T-cell receptor (TCR), and other protein engineering—into a single conversational interface. The platform performs proprietary structural modeling, variant generation, and biologics optimisation to help scientists design development-ready therapeutic candidates. Complementing the platform, Etcembly offers Custom Workflows for bespoke AI-driven discovery services such as proprietary immune sequencing, functional immune discovery, antibody expression enhancement, and co-complex prediction.

Is Etcembly a public or private company?

Etcembly is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Etcembly founded?

Etcembly was founded in 2020. It employs 11 to 50 people.

Where is Etcembly based?

Etcembly is headquartered in Hanwell, United Kingdom, in the Europe region.

How does Etcembly make money?

One revenue line is on record: EMLy Co-pilot Platform Access.

Who are Etcembly's main competitors?

Emerging players on record are Cradle Bio and Antiverse. Direct peers are LabGenius, Insitro, Generate Biomedicines and BigHat Biosciences. BenchSci is listed as an others. Broad incumbents are Isomorphic Labs, Recursion Pharmaceuticals and AbCellera Biologics.

Does Etcembly have an API?

No public API is recorded for Etcembly.

What industry is Etcembly in?

Etcembly's product category is AI Biologics Discovery Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireZelluna ASA: First Quarter 2026 resultsZelluna reported Q1 2026 results, activating its first clinical site in the UK for the ZIMA-101 study. The company recorded total operating expenses of MNOK 20.4 and a cash position of MNOK 49.3, with operations expected to last into Q1 2027.GlobeNewswireZelluna announces collaboration with Etcembly for AI-enabled TCR engineeringZelluna announced a collaboration with Etcembly to engineer AI-enabled TCRs targeting the cancer antigen KKLC1 for its TCR-NK platform. The partnership builds on the successful engineering of the MAGE-A4-targeting TCR for ZI-MA4-1, which received UK MHRA approval in February 2026. In-vitro data on the new TCRs is expected in Q4 2026.BioSpaceZelluna announces collaboration with Etcembly for AI-enabled TCR engineeringZelluna, a Norwegian biotech company listed on the Oslo Stock Exchange, has entered into a collaboration with Etcembly Ltd to engineer high-affinity T cell receptors (TCRs) targeting the KKLC1 cancer antigen for use in its allogeneic TCR-NK cell therapy platform for treating solid cancers. The collaboration builds on their previous successful partnership that produced ZI-MA4-1, which received UK MHRA approval for clinical testing in February 2026, with in-vitro data from the new KKLC1 program expected in Q4 2026. By expanding its target portfolio to KKLC1, Zelluna aims to address a broader spectrum of solid cancers beyond the MAGE-A4 antigen targeted by its lead product candidate.TracxnTop Companies in Drug Formulation Tools (Oct, 2025)This article presents a list of top startups in the drug formulation tools sector, highlighting companies such as Etcembly, Promise, and Archon Bio that utilize AI for therapeutic development. It notes that these startups are often founded by alumni from prestigious institutions like Harvard University and the University of Cambridge. The report provides specific details on funding rounds and operational locations for each featured entity.TmcnetVector Laboratories Announces Partnership With British Biotech Innovator EtcemblyVector Laboratories announced a partnership with British biotech Etcembly to accelerate recombinant antibody development. Vector will provide antibody sequences with manufacturability issues, and Etcembly will use its AI platform to generate optimized sequences. The collaboration aims to improve antibody production for cancer therapies.Business Wire BlogVector Laboratories Announces Partnership With British Biotech Innovator EtcemblyVector Laboratories announced a partnership with British biotech Etcembly to use Etcembly's AI platform to optimize antibody engineering. Vector will provide antibody sequences with manufacturability issues, and Etcembly will generate updated sequences for improved yield and aggregation. The collaboration aims to accelerate development of recombinant antibody therapeutics.YahooVector Laboratories Announces Partnership With British Biotech Innovator EtcemblyVector Laboratories announced a partnership with British biotech Etcembly to accelerate recombinant antibody therapeutics. Vector will provide antibody sequences with manufacturability issues, and Etcembly will use its AI platform to generate optimized sequences. The collaboration aims to improve antibody manufacturability and accelerate novel antibody development.Business Wire BlogEtcembly Launches Groundbreaking Research Study Searching for Cancer Cures in SurvivorsEtcembly launched the ETCh study, recruiting cancer survivors and healthy volunteers aged 18-65 to donate blood up to five times over a year. The study will sequence millions of antibodies and T cell receptors, using Etcembly's AI platform to identify new cancer targets for immunotherapies. New targets are expected within 12-18 months.Bebeez13 techbio startups to watch, according to investors – BeBeez InternationalEuropean techbio startups raised €1.69bn in funding up to August 22, with the UK dominating deal count. Munich led in funding at €275.5m, driven by ITM Radiopharma's €188m raise. Investors are watching 13 non-portfolio companies, including Sixfold Bioscience and Etcembly.ForbesHow Generative AI Will Change Jobs In HealthcareGenerative AI is set to transform healthcare by aiding diagnosis, drug discovery, and administrative tasks. It can analyze medical images and generate personalized treatment plans, with examples like Etcembly's AI-designed immunotherapy. Ethical and regulatory challenges remain, requiring professionals to adapt their roles.